Cargando…
Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models
Neuritic plaques in the brains are one of the pathological hallmarks of Alzheimer's disease (AD). Amyloid β-protein (Aβ), the central component of neuritic plaques, is derived from β-amyloid precursor protein (APP) after β- and γ-secretase cleavage. The molecular mechanism underlying the pathog...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585842/ https://www.ncbi.nlm.nih.gov/pubmed/18955571 http://dx.doi.org/10.1084/jem.20081588 |
_version_ | 1782160865708998656 |
---|---|
author | Qing, Hong He, Guiqiong Ly, Philip T. T. Fox, Christopher J. Staufenbiel, Matthias Cai, Fang Zhang, Zhuohua Wei, Shengcai Sun, Xiulian Chen, Chia-Hsiung Zhou, Weihui Wang, Ke Song, Weihong |
author_facet | Qing, Hong He, Guiqiong Ly, Philip T. T. Fox, Christopher J. Staufenbiel, Matthias Cai, Fang Zhang, Zhuohua Wei, Shengcai Sun, Xiulian Chen, Chia-Hsiung Zhou, Weihui Wang, Ke Song, Weihong |
author_sort | Qing, Hong |
collection | PubMed |
description | Neuritic plaques in the brains are one of the pathological hallmarks of Alzheimer's disease (AD). Amyloid β-protein (Aβ), the central component of neuritic plaques, is derived from β-amyloid precursor protein (APP) after β- and γ-secretase cleavage. The molecular mechanism underlying the pathogenesis of AD is not yet well defined, and there has been no effective treatment for AD. Valproic acid (VPA) is one of the most widely used anticonvulsant and mood-stabilizing agents for treating epilepsy and bipolar disorder. We found that VPA decreased Aβ production by inhibiting GSK-3β–mediated γ-secretase cleavage of APP both in vitro and in vivo. VPA treatment significantly reduced neuritic plaque formation and improved memory deficits in transgenic AD model mice. We also found that early application of VPA was important for alleviating memory deficits of AD model mice. Our study suggests that VPA may be beneficial in the prevention and treatment of AD. |
format | Text |
id | pubmed-2585842 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-25858422009-05-24 Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models Qing, Hong He, Guiqiong Ly, Philip T. T. Fox, Christopher J. Staufenbiel, Matthias Cai, Fang Zhang, Zhuohua Wei, Shengcai Sun, Xiulian Chen, Chia-Hsiung Zhou, Weihui Wang, Ke Song, Weihong J Exp Med Articles Neuritic plaques in the brains are one of the pathological hallmarks of Alzheimer's disease (AD). Amyloid β-protein (Aβ), the central component of neuritic plaques, is derived from β-amyloid precursor protein (APP) after β- and γ-secretase cleavage. The molecular mechanism underlying the pathogenesis of AD is not yet well defined, and there has been no effective treatment for AD. Valproic acid (VPA) is one of the most widely used anticonvulsant and mood-stabilizing agents for treating epilepsy and bipolar disorder. We found that VPA decreased Aβ production by inhibiting GSK-3β–mediated γ-secretase cleavage of APP both in vitro and in vivo. VPA treatment significantly reduced neuritic plaque formation and improved memory deficits in transgenic AD model mice. We also found that early application of VPA was important for alleviating memory deficits of AD model mice. Our study suggests that VPA may be beneficial in the prevention and treatment of AD. The Rockefeller University Press 2008-11-24 /pmc/articles/PMC2585842/ /pubmed/18955571 http://dx.doi.org/10.1084/jem.20081588 Text en © 2008 Qing et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/). |
spellingShingle | Articles Qing, Hong He, Guiqiong Ly, Philip T. T. Fox, Christopher J. Staufenbiel, Matthias Cai, Fang Zhang, Zhuohua Wei, Shengcai Sun, Xiulian Chen, Chia-Hsiung Zhou, Weihui Wang, Ke Song, Weihong Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models |
title | Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models |
title_full | Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models |
title_fullStr | Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models |
title_full_unstemmed | Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models |
title_short | Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models |
title_sort | valproic acid inhibits aβ production, neuritic plaque formation, and behavioral deficits in alzheimer's disease mouse models |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585842/ https://www.ncbi.nlm.nih.gov/pubmed/18955571 http://dx.doi.org/10.1084/jem.20081588 |
work_keys_str_mv | AT qinghong valproicacidinhibitsabproductionneuriticplaqueformationandbehavioraldeficitsinalzheimersdiseasemousemodels AT heguiqiong valproicacidinhibitsabproductionneuriticplaqueformationandbehavioraldeficitsinalzheimersdiseasemousemodels AT lyphiliptt valproicacidinhibitsabproductionneuriticplaqueformationandbehavioraldeficitsinalzheimersdiseasemousemodels AT foxchristopherj valproicacidinhibitsabproductionneuriticplaqueformationandbehavioraldeficitsinalzheimersdiseasemousemodels AT staufenbielmatthias valproicacidinhibitsabproductionneuriticplaqueformationandbehavioraldeficitsinalzheimersdiseasemousemodels AT caifang valproicacidinhibitsabproductionneuriticplaqueformationandbehavioraldeficitsinalzheimersdiseasemousemodels AT zhangzhuohua valproicacidinhibitsabproductionneuriticplaqueformationandbehavioraldeficitsinalzheimersdiseasemousemodels AT weishengcai valproicacidinhibitsabproductionneuriticplaqueformationandbehavioraldeficitsinalzheimersdiseasemousemodels AT sunxiulian valproicacidinhibitsabproductionneuriticplaqueformationandbehavioraldeficitsinalzheimersdiseasemousemodels AT chenchiahsiung valproicacidinhibitsabproductionneuriticplaqueformationandbehavioraldeficitsinalzheimersdiseasemousemodels AT zhouweihui valproicacidinhibitsabproductionneuriticplaqueformationandbehavioraldeficitsinalzheimersdiseasemousemodels AT wangke valproicacidinhibitsabproductionneuriticplaqueformationandbehavioraldeficitsinalzheimersdiseasemousemodels AT songweihong valproicacidinhibitsabproductionneuriticplaqueformationandbehavioraldeficitsinalzheimersdiseasemousemodels |